Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 5/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510732 | 0.89 | PTGES2 (0.41) | PTGESPTGES2MCL1PTPN1TRPV1 | |
| SCHEMBL4503637 | 0.87 | PTGES (0.40) | PTGESPTGES2MCL1TRPV1CA2 | |
| SCHEMBL4510010 | 0.85 | PTGES (0.36) | PTGESPTGES2MCL1PTPN1TRPV1 | |
| SCHEMBL4511441 | 0.83 | PTGES (0.40) | PTGESMCL1CA2CA1CA9 | |
| SCHEMBL4506540 | 0.83 | PTGES (0.40) | PTGESMCL1CA2CA1CA9 | |
| SCHEMBL4516473 | 0.81 | PTGES (0.37) | PTGESPTPN1TRPV1CA2CA1 | |
| SCHEMBL4503529 | 0.81 | ESR1 (0.41) | PTGESMCL1CA2CA1CA9 | |
| SCHEMBL4491363 | 0.81 | ESR1 (0.43) | PTGESPTGES2TRPV1CA2CA1 | |
| SCHEMBL4505853 | 0.80 | PTGES (0.46) | PTGESMCL1CA2CA1CA9 | |
| SCHEMBL4497864 | 0.80 | ESR1 (0.42) | PTGESKAT6ATRPV1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234014-A1 | Naphthalene-Disulfonamides Useful for the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234014-A1 | Naphthalene-Disulfonamides Useful for the Treatment of Inflammation | AREG, PRSS12, CXCL8 | PTGES 41/4885PTGES2 110/4885KAT6A 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.